Ulisse Biomed Statistics
Total Valuation
Ulisse Biomed has a market cap or net worth of EUR 16.88 million. The enterprise value is 16.09 million.
Market Cap | 16.88M |
Enterprise Value | 16.09M |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
Earnings Date | Mar 28, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Ulisse Biomed has 22.03 million shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 22.03M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 39.68 |
PB Ratio | 0.68 |
P/TBV Ratio | 4.32 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -2.31 |
EV / Sales | 38.21 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.36, with a Debt / Equity ratio of 0.02.
Current Ratio | 2.36 |
Quick Ratio | 1.43 |
Debt / Equity | 0.02 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -471.58 |
Financial Efficiency
Return on equity (ROE) is -46.78% and return on invested capital (ROIC) is -29.40%.
Return on Equity (ROE) | -46.78% |
Return on Assets (ROA) | -25.89% |
Return on Capital (ROIC) | -29.40% |
Revenue Per Employee | 52,616 |
Profits Per Employee | -870,816 |
Employee Count | 10 |
Asset Turnover | 0.02 |
Inventory Turnover | 1.73 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.47% in the last 52 weeks. The beta is 0.59, so Ulisse Biomed's price volatility has been lower than the market average.
Beta (5Y) | 0.59 |
52-Week Price Change | -55.47% |
50-Day Moving Average | 0.87 |
200-Day Moving Average | 1.06 |
Relative Strength Index (RSI) | 31.75 |
Average Volume (20 Days) | 21,300 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ulisse Biomed had revenue of EUR 420,924 and -6.97 million in losses. Loss per share was -0.32.
Revenue | 420,924 |
Gross Profit | -1.45M |
Operating Income | -7.11M |
Pretax Income | -6.97M |
Net Income | -6.97M |
EBITDA | -6.33M |
EBIT | -7.11M |
Loss Per Share | -0.32 |
Balance Sheet
The company has 1.23 million in cash and 434,773 in debt, giving a net cash position of 790,598 or 0.04 per share.
Cash & Cash Equivalents | 1.23M |
Total Debt | 434,773 |
Net Cash | 790,598 |
Net Cash Per Share | 0.04 |
Equity (Book Value) | 24.74M |
Book Value Per Share | 1.13 |
Working Capital | 2.88M |
Cash Flow
Operating Cash Flow | n/a |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | -1,689.04% |
Pretax Margin | -1,655.06% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Ulisse Biomed does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -41.71% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Ulisse Biomed has an Altman Z-Score of 2.14. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.14 |
Piotroski F-Score | n/a |